Skip to main content
. 2022 Dec 18;10(5):2205483. doi: 10.1002/advs.202205483

Figure 8.

Figure 8

Sorafenib and Regorafenib inhibit osteosarcoma lung metastases through the PINK1/Rab22a‐NeoF1 axis. a) 143B and U2OS/MTX300 cells stably expressing Rab22a‐NeoF1‐SFB were treated with Sorafenib (5 × 10−6 m) or Regorafenib (5 × 10−6 m) for 12 h as indicated, and cell lysates were subjected to western blot. The experiments were repeated three times independently with similar results. b,c) Quantification analyses of migration and invasion assays using the indicated stable cells under treatment of control, Sorafenib (5 × 10−6 m), or Regorafenib (5 × 10−6 m). The depicted results are the averages of at least three independent experiments. The data are presented as the mean ± SD. A two‐sided unpaired student's t‐test was performed, and p values are shown. d) The procedure for in vivo orthotropic model of osteosarcoma metastasis under treatment of control, Sorafenib (5 × 10−6 m), or Regorafenib (5 × 10−6 m). e,f) In vivo orthotropic model of osteosarcoma metastasis using 143B‐Luc cells stably expressing Rab22a‐NeoF1 wild type (WT), K112A mutant, S120A mutant, WT plus PINK1, or S120A mutant plus PINK1 as indicated under treatment of control, Sorafenib (5 × 10−6 m), or Regorafenib (5 × 10−6 m) (n = 6 biologically independent animals). e) Representative images of mice. f) Quantification analyses of lung metastases in mice.